)
Visual24 Oct 2025
The rise of Alphabet
OSE Immunotherapeutics (OSE) investor relations material
OSE Immunotherapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary25 Sep, 2025
Executive summary
Advanced clinical programs in immuno-oncology and immuno-inflammation, with Tedopi® in phase 3 for lung cancer and Lusvertikimab showing positive phase 2 results in ulcerative colitis.
Strategic partnerships with AbbVie, Boehringer Ingelheim, and Veloxis, and a new AI collaboration with Scienta Lab to enhance precision immunology.
Governance changes included a new Chief Development Officer and interim CEO, with a full board renewal in September 2025.
Cash position as of June 30, 2025, was €41.6 million, down from €64.2 million at December 31, 2024.
Delay anticipated in the Phase 1 trial initiation for ABBV-230, impacting expected milestone payments.
Financial highlights
Revenue for H1 2025 was €1.3M, sharply down from €69.0M in H1 2024, reflecting the absence of major upfront payments recognized last year.
Net loss of €15.1M in H1 2025, compared to a net profit of €57.2M in H1 2024, due to lower revenue and sustained R&D investment.
R&D expenses increased slightly to €14.8M, with general expenses at €4.5M and share-based payment charges at €2.2M.
Cash and cash equivalents totaled €25.4 million; fixed-term deposits classified as current and non-current financial assets were €16.2 million as of June 30, 2025.
Cash position decreased by €22.6 million compared to December 31, 2024.
Outlook and guidance
Current cash runway extends to early Q4 2026, assuming capital increases, R&D tax credits, grants, and full exercise of remaining warrants.
If anticipated milestones are received in 2026, cash runway could extend to at least Q1 2027.
Additional financing or debt restructuring will be required to cover activities beyond this horizon.
Several options under evaluation to extend runway, including new partnerships, equity financing, and debt restructuring.
Ongoing strategic review to explore partnerships and funding options.
How does ABBV-230 delay impact cash runway?
Detail plans to extend cash runway beyond 2026.
Calculate H1 2025 cash usage.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next OSE Immunotherapeutics earnings date
H2 202525 Mar, 2026
Next OSE Immunotherapeutics earnings date
H2 202525 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
OSE Immunotherapeutics SA is a French biotechnology company focused on developing immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company’s pipeline includes innovative treatments aimed at modulating the immune system, including checkpoint inhibitors, therapeutic vaccines, and monoclonal antibodies. OSE Immunotherapeutics leverages proprietary technology platforms to design therapies that target specific immune pathways, with the goal of improving patient outcomes in conditions where immune response plays a critical role. The company collaborates with research institutions and pharmaceutical companies to advance its clinical programs. The company is headquartered in Nantes, France, and its shares are listed on Euronext Paris.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage